- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last? | 1 | Zacks | ||
| 09.06. | CVRx CFO Oasheim To Step Down | 1 | RTTNews | ||
| 09.06. | CVRx CFO Jared Oasheim to step down | 1 | Seeking Alpha | ||
| CVRX Aktie jetzt für 0€ handeln | |||||
| 09.06. | CVRx, Inc.: CVRx Announces Chief Financial Officer Transition | 237 | GlobeNewswire (Europe) | MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation... ► Artikel lesen | |
| 03.06. | CVRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | CVRx earns Humana Medicare Advantage win for Barostim | 1 | MassDevice | ||
| 14.05. | CVRx rebounds as Humana issues Medicare policy for Barostim | 2 | Seeking Alpha | ||
| 14.05. | CVRx, Inc.: CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy | 2 | GlobeNewswire (USA) | ||
| 12.05. | CVRx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | CVRx signals $63M-$67M 2026 revenue outlook as Category I CPT transition reshapes prior authorization dynamics | 1 | Seeking Alpha | ||
| 11.05. | CVRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.05. | CVRx enrolls first patient in 2,500-patient heart failure trial | 2 | Investing.com | ||
| 04.05. | CVRx enrolls first patient in study of Barostim therapy for heart failure | - | MassDevice | ||
| 04.05. | CVRx, Inc.: CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population | 112 | GlobeNewswire (Europe) | MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for... ► Artikel lesen | |
| 01.05. | CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 20.04. | CVRx nominates Michael Dale to board of directors | 4 | Investing.com | ||
| 20.04. | CVRx nominiert Michael Dale für den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 20.04. | CVRx, Inc.: CVRx Announces Nomination of Michael Dale for Election to the Board of Directors | 2 | GlobeNewswire (USA) | ||
| 13.04. | William Blair reiterates CVRx stock rating on strong Q1 results | 2 | Investing.com | ||
| 13.04. | CVRx sees Q1 revenue in the range of $14.7M to $14.8M | 2 | Seeking Alpha |
1 2 3 Weiter >>
46 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO-DIAGNOSTICS | 3,080 | 0,00 % | Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test | More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs
Analytical... ► Artikel lesen | |
| CYTOSORBENTS | 0,352 | 0,00 % | Cytosorbents Corp - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,690 | -1,26 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| FULGENT GENETICS | 18,000 | -2,17 % | Fulgent reports interim data for cancer drug FID-007 trial | ||
| EMBECTA | 2,857 | -3,38 % | Embecta Corp.: embecta appoints Nimish Muzumdar as SVP and President, North America | PARSIPPANY, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical... ► Artikel lesen | |
| CHECK-CAP | 1,080 | 0,00 % | Check-Cap Ltd - 6-K, Report of foreign issuer | ||
| ELECTROCORE | 7,350 | +6,52 % | electroCore, Inc.: electroCore Announces Full Year 2025 Financial Results and Organizational Changes | Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness... ► Artikel lesen | |
| CATHETER PRECISION | 0,850 | -0,01 % | What's Going On With Catheter Precision Stock On Friday? | ||
| CLEARPOINT NEURO | 18,720 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint | Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including... ► Artikel lesen | |
| ENVUE MEDICAL | 0,570 | -0,02 % | ENvue Medical, Inc.: ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network | TYLER, Texas, June 05, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) ("ENvue," "ENvue Medical," or the "Company"), a commercial-stage medical device company focused on real-time guided bedside... ► Artikel lesen | |
| FIREFLY NEUROSCIENCE | 1,300 | +0,78 % | Firefly Neuroscience, Inc.: Firefly Confirms Public-Private Partnership with the Department of War | Firefly's AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of... ► Artikel lesen | |
| EXAGEN | 4,000 | -2,44 % | Exagen Inc. Reports First Quarter 2026 Results | CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026... ► Artikel lesen | |
| ENDRA LIFE SCIENCES | 4,960 | -1,59 % | ASP Isotopes Inc.: ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing | Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen's Virginia Gas Project Listing expected to provide investors with direct exposure to one of... ► Artikel lesen | |
| FEMASYS | 4,290 | -1,38 % | Femasys Inc.: Femasys Regains Compliance with Nasdaq Listing Requirements | ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective... ► Artikel lesen | |
| CUPRINA HOLDINGS | 5,800 | -2,68 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
Das Unternehmen CVRX INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CVRX INC finden Sie auf Wallstreet Online.